EULAR

Switching Among Multiple Infliximab Biosimilars Does Not Cause Immunogenicity, Study Finds

June 17th 2019

A new study has found that switching among multiple biosimilar infliximab products was not associated with increased immunogenicity in patients with inflammatory diseases.

In the Short Term, Most Patients With RA Remain on a Biosimilar Post Switch

June 16th 2019

Article

During this week’s European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, researchers from the University of Manchester reported on their findings regarding patients with rheumatoid arthritis (RA) involved in the BSRBR-RA study who had switched from reference infliximab or reference etanercept to biosimilars.

Biosimilar Adalimumab, Hulio, Is Safe Long-Term, Causes Less Injection-Site Pain Than Humira

June 14th 2019

Article

During this week’s European League Against Rheumatism Annual European Congress of Rheumatology, researchers will present on the long-term safety, immunogenicity, and efficacy of the biosimilar versus the reference in an open-label extension study that involved switching between the biosimilar and the reference.

Studies Disagree on the Role of Education, Nocebo Effect in Biosimilar Switching

June 13th 2019

Article

During this week’s European League Against Rheumatism European Congress of Rheumatology 2019, 2 research teams will present their contrasting findings on education and the nocebo effect.

Real-World Data on SB4 Highlight Biosimilar Etanercept's Efficacy

June 12th 2019

Article

During this week’s European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, multiple teams of researchers will present their findings on real-world evidence of the biosimilar’s efficacy and the feasibility of switching to SB4 from the reference etanercept, Enbrel.

9 Biosimilar Takeaways from the 2018 EULAR Congress

June 24th 2018

Article

Biosimilars featured prominently in research presented at the European League Against Rheumatism's Annual European Congress of Rheumatology. Here are 9 key takeaways from the meeting.

Low-Dose Biosimilar Rituximab Is Effective in Treating RA

June 17th 2018

Article

Rituximab has previously been shown to be effective at doses of 1000 mg in treating patients with rheumatoid arthritis (RA) who had previously received other biologic agents. Research presented at the European League Against Rheumatism's Annual European Congress of Rheumatology demonstrates that using lower doses of biosimilar rituximab—which may provide a substantial cost savings—is also effective.

Three Studies Document Switches to Biosimilar Etanercept

June 15th 2018

Article

At the European League Against Rheumatism Annual European Congress of Rheumatology, researchers presented findings on 3 studies in which patients switched to a biosimilar etanercept molecule from the reference Enbrel.

Researchers Present Findings on Biosimilar Adalimumab Products

June 14th 2018

Article

During the European League Against Rheumatism’s Annual European Congress of Rheumatology, held from June 13-16 in Amsterdam, Netherlands, researchers presented findings on adalimumab biosimilars, referencing Humira.

Researchers Report on Infliximab Biosimilars BCD-055 and CT-P13

June 14th 2018

Article

At the European League Against Rheumatism (EULAR)'s Annual European Congress of Rheumatology, held from June 13-16 in Amsterdam, Netherlands, researchers reported on Biocad’s Russian-authorized biosimilar infliximab, BCD-055, and on switches to the widely approved infliximab biosimilar CT-P13 (Inflectra, Remsima).